Impact of estimated total blood volume on NT-proBNP response to angiotensin receptor-neprilysin inhibition in acute heart failure: insights from the PREMIER study.

Authors

Kazutaka Nogi, Atsushi Tanaka, Takumi Imai, Shunichi Doi, Kohei Kamishita, Hideki Kawai, Masaru Obokata, Keisuke Kida, Yuya Matsue, Hideo Izawa, Shungo Hikoso, Koichi Node, PREMIER Study Investigators

Published in

American heart journal. Pages 107549. Aug 01, 2026. Epub Aug 01, 2026.

Abstract

Sacubitril/valsartan (Sac/Val) reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in acute heart failure (AHF), particularly in patients with reduced ejection fraction. However, whether estimated total blood volume (TBV), calculated using anthropometric equations, is associated with heterogeneity in biomarker response remains uncertain.
This post hoc exploratory sub-analysis of the PREMIER randomized trial evaluated whether baseline estimated TBV was associated with heterogeneity in NT-proBNP reduction after Sac/Val compared with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy. Estimated TBV was calculated using validated anthropometric equations and dichotomized at the median (4.05 L). Patients were further stratified by left ventricular ejection fraction (LVEF <40% vs. ≥40%). The primary endpoint was the proportional change in NT-proBNP from baseline to Week 8.
Among 376 patients, 372 with baseline estimated TBV data were analyzed. In the high TBV group, Sac/Val was associated with greater NT-proBNP reduction than ACEI/ARB (-56% vs. -32%; ratio of change, 0.67; 95% confidence interval, 0.53-0.84; P=0.001), whereas no significant difference was observed in the low TBV group (P for heterogeneity=0.063). In patients with LVEF <40%, Sac/Val was associated with greater NT-proBNP reduction in both TBV groups. In patients with LVEF ≥40%, Sac/Val was associated with greater NT-proBNP reduction in the high TBV group, whereas the point estimate in the low TBV group numerically favored ACEI/ARB.
In this exploratory post hoc analysis, higher estimated TBV was associated with greater NT-proBNP reduction after Sac/Val, particularly among patients with LVEF ≥40%. These findings are hypothesis-generating and require external validation.
ClinicalTrials.gov, NCT05164653; Japan Registry of Clinical Trials, jRCTs021210046.

PMID:
42542200
Bibliographic data and abstract were imported from PubMed on 02 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.